THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study ...
On Jan. 1, 2026, the price of my medication finally came down — and it will change my life. I have been living with psoriatic arthritis for over 40 years, a condition that I treat with a medication ...
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., JUNE 19, 2003 – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today ...
After back-to-back losses in court, Novartis’ generics outfit Sandoz had hoped the U.S. Supreme Court would take up its long shot biosimilars case against Enbrel maker Amgen. But now that effort has ...
An appeals court ruling means biosimilar competition won't affect U.S. Enbrel sales for a long time. Enbrel is a tumor necrosis factor (TNF) inhibitor that earned its first FDA approval all the way ...
Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the ...
Amgen last summer scored a major patent win to defend its blockbuster immunology med Enbrel from impending biosimilar competition. Now, Novartis is challenging that ruling in appeals court, but ...
On Monday, May 17 th, the U.S. Supreme Court decided not to take up Sandoz’s petition for the Court to review previous lower court decisions on the launch of its biosimilar product. This included a ...
Last week, the Federal Circuit denied Sandoz’s petition for an en banc rehearing of its precedential July 1st panel decision upholding two of Immunex’s patents covering Enbrel®. As explained in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback